• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • Biblioteca
  • Museu
  • Pessoal
    • Webmail
    • Área de Docentes
    • Área de Não-Docentes
  • Estudantes
    • Webmail
    • Moodle
    • NetP@
    • Escola Doutoral
    • Serviços Académicos
    • Trabalhar no IHMT

IHMT

Instituto de Higiene e Medicina Tropical

  • O Instituto
    • Missão
    • Mensagem do Diretor
    • Órgãos de governo
    • Docentes e investigadores
    • Portal de Denúncias UNL
  • Ensino
    • Mestrados
    • Doutoramentos
    • Cursos de Especialização
    • Formação transversal
    • Cursos de Curta Duração
    • Ensino à Distância
    • Apoio ao Desenvolvimento
    • Serviços académicos
    • NOVA Open Academy
  • Investigação
    • Centro GHTM
    • Unidades de Ensino e de Investigação (UEI)
      • Unidade de Clínica Tropical
      • Unidade de Microbiologia Médica
      • Unidade de Parasitologia Médica
      • Unidade de Saúde Pública Global
      • Serviço de Apoio à Ciência e Comunidade
    • Biobanco
    • BLOODless
    • Centro Colaborador OMS
    • Publicações
  • Serviços e gestão
    • Biblioteca
    • Sistema de Qualidade
    • Estatutos e regulamentos
    • Plano de Atividades
    • Relatório de Atividades
    • Relatório de Gestão
    • Contratos públicos
    • Recursos humanos
      • Concursos e bolsas
        • Concursos – Docentes e Investigadores
        • Concursos – Não Docentes e Não Investigadores
        • Bolsas de Investigação
      • Contratos
      • Avaliação de Desempenho
        • Ciclo Avaliativo
          • Biénio 2021-2022
          • Biénio 2023-2024
        • Conselho Coordenador de Avaliação
        • Comissão Paritária
      • Mobilidade
      • Listas Nominativas
  • Doenças Tropicais
    • Consulta do Viajante
    • Dossiês Informativos
    • Glossário
    • Museu
    • Vídeos
    • MosquitoWeb
  • Comunidade
    • Cooperação e Desenvolvimento
    • Formação
    • Parcerias
  • Contactos
  • Candidaturas
  • pt
    • pt
    • en
Home / Archives for Molnar J

Molnar J

Therapy Of XDR TB with thioridazine a drug beyond patent protection but eligible for patent “as new use”

  • Autores: Amaral L, Molnar J
  • Ano de Publicação: 2010
  • Journal: Recent Patents on Anti-Infective Drug Discovery
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Therapy+of+XDR-TB+with+thioridazine+a+drug+beyond+patent+protection+but+eligible+for+patent+%E2%80%9Cas+new+use

Mycobacterium tuberculosis that is resistant to Isoniazid (INH) and Rifampin (Rif) and hence, multi-drug resistant (MDR) has progressed to extensive drug resistant (XDR) status. XDR strains of Mycobacterium tuberculosis (XDR Mtb) are resistant, in addition to INH and Rif, to any fluoroquinolone, streptomycin and to any of the injectable anti-TB drugs kanamycin, amikacin and capreomycin.
Ler mais

Antibacterial properties of compounds isolated from Carpobrotus edulis.

  • Autores: Amaral L, Hohmann J, Martins A, Molnar J, Vasas A, Viveiros M
  • Ano de Publicação: 2011
  • Journal: International Journal of Antimicrobial Agents
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/21411294

Several compounds isolated from the plant Carpobrotus edulis were evaluated for their activity against multidrug-resistant (MDR) bacteria and their efflux pump systems.
Ler mais

Genetic response of Salmonella enterica serotype Enteritidis to thioridazine rendering the organism resistant to the agent.

  • Autores: Amaral L, Cerca P, Costa SS, Couto I, Fanning S, Machado L, Martins A, Martins M, McCusker M, Molnar J, Ntokou E, Rodrigues L, Spengler G, Viveiros M
  • Ano de Publicação: 2012
  • Journal: International Journal of Antimicrobial Agents
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Genetic+response+of+Salmonella+enterica+serotype+Enteritidis+to+thioridazine+rendering+the+organism+resistant+to+the+agent

Thioridazine (TZ)-induced accumulation of the universal efflux pump substrate ethidium bromide and its subsequent efflux by Salmonella strains with various degrees of overexpressed efflux pumps takes place automatically at pH 7.4, is independent of a metabolic source, is not affected by a proton ionophore and is precluded by palmitic acid.
Ler mais

Phenothiazines, bacterial efflux pumps and targeting the macrophage for enhanced killing of intracellular XDRTB

  • Autores: Amaral L, Couto I, Dastidar S, Fanning S, Kristiansen JE, Martins A, Martins M, McCusker M, Molnar J, Pagès JM, Ramos J, Rodrigues L, Spengler G, Viveiros M
  • Ano de Publicação: 2010
  • Journal: In vivo
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Phenothiazines%2C+bacterial+efflux+pumps+and+targeting+the+macrophage+for+enhanced+killing+of+intracellular+XDRTB

Phenothiazines have their primary effects on the plasma membrane of prokaryotes and eukaryotes. Among the components of the prokaryotic plasma membrane affected are efflux pumps, their energy sources, energy providing enzymes such as ATPases, and genes that regulate and code for permeability aspects of the bacterium.
Ler mais

Activity of the efflux pump inhibitor SILA 421 against drug-resistant tuberculosis

  • Autores: Amaral L, Boeree MJ, Christensen JB, Hajos G, Kristiansen JE, Molnar J, Riedl Z, Simons SO, Van Der Laan T, Van Ingen J, Van Soolingen D, Viveiros M
  • Ano de Publicação: 2013
  • Journal: International Journal of Antimicrobial Agents
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/23410790

Ler mais

Therapy Of XDR TB with thioridazine a drug beyond patent protection but eligible for patent “as new use”

  • Autores: Amaral L, Molnar J
  • Ano de Publicação: 2010
  • Journal: Recent Patents on Anti-Infective Drug Discovery
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Therapy+of+XDR-TB+with+thioridazine+a+drug+beyond+patent+protection+but+eligible+for+patent+%E2%80%9Cas+new+use%E2%80%9D

Mycobacterium tuberculosis that is resistant to Isoniazid (INH) and Rifampin (Rif) and hence, multi-drug resistant (MDR) has progressed to extensive drug resistant (XDR) status. XDR strains of Mycobacterium tuberculosis (XDR Mtb) are resistant, in addition to INH and Rif, to any fluoroquinolone, streptomycin and to any of the injectable anti-TB drugs kanamycin, amikacin and capreomycin.
Ler mais

Inhibition of quorum sensing and efflux pump system by trifluoromethyl ketone proton pump inhibitors.

  • Autores: Amaral L, Armada A, Cerca P, Kawase M, Mior Ahmad Subki MA, Molnar J, Motohashi N, Savka MA, Szegedi E, Varga ZG
  • Ano de Publicação: 2012
  • Journal: In vivo
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Inhibition+of+Quorum+Sensing+and+Efflux+Pump+System+by+Trifluoromethyl+Ketone+Proton+Pump+Inhibitors

BACKGROUND:
One major microbiological problem is the widespread antibiotic resistance. There is an urgent need for new antibiotics and ways to treat multi-drug-resistant infections. Inhibition of bacterial quorum sensing (QS) systems could be an effective alternative in a smuch as they regulate a broad spectrum of cell functions, including, virulence factor production, biofilm organisation and motility. Influx and efflux bacterial systems involved in quorum sensing (QS) are known to depend on the proton motive force (PMF). Thus, a new series of 12 trifluoromethyl ketones (TFs) known to inhibit the PMF, was investigated for effects on the efflux pump of a QS responding bacterium, for its subsequent effect on the response to a QS signal and its direct inhibition of the response to a QS signal.
Ler mais

Activity of fourteen new hydantoin compounds on the human ABCB1 efflux pump.

  • Autores: Amaral L, Armada A, Dymek A, Handzlik J, Kiec-Kononowicz K, Martins A, Molnar J, Spengler G
  • Ano de Publicação: 2012
  • Journal: In vivo
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Activity+of+Fourteen+New+Hydantoin+Compounds+on+the+Human+ABCB1+Efflux+Pump

BACKGROUND:
Multidrug resistance (MDR) is one of the major concerns in the treatment of cancer and one of the major causes of therapy failure. The overexpression of an ABC transporter, the ABCB1, is often associated with MDR in cancer. Previously it was observed that hydantoin compounds can modulate the activity of the ABCB1 pump.
Ler mais

The activity of 16 new hydantoin compounds on the intrinsic and overexpressed efflux pump system of Staphylococcus aureus.

  • Autores: Amaral L, Armada A, Dymek A, Handzlik J, Kiec-Kononowicz K, Molnar J, Spengler G, Viveiros M
  • Ano de Publicação: 2012
  • Journal: In vivo
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=The+Activity+of+16+New+Hydantoin+Compounds+on+the+Intrinsic+and+Overexpressed+Efflux+Pump+System+of+Staphylococcus+aureus

AIM:
To evaluate a new series of 16 hydantoin derivatives for activity against the intrinsic and overexpressed efflux pumps of the ATTC 25923 Staphylococcus aureus and the clinical Staphylococcus aureus HPV-107 strain, respectively.
Ler mais

Potential therapy of multidrug-resistant and extremely drug-resistant tuberculosis with thioridazine.

  • Autores: Amaral L, Molnar J
  • Ano de Publicação: 2012
  • Journal: In vivo
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/22351663

Multidrug-resistant tuberculosis (MDRTB) infections that continue to increase in frequency globally have progressed to become extremely drug-resistant tuberculosis (XDRTB). The therapeutic problems associated with MDRTB pale in comparison to those for XDRTB where mortality is high.
Ler mais

  • Page 1
  • Page 2
  • Page 3
  • Go to Next Page »

Footer

INSTITUTO DE HIGIENE E
MEDICINA TROPICAL
UNIVERSIDADE NOVA DE LISBOA
Rua da Junqueira, 100 1349-008 Lisboa
T +351 213 652 600
geral@ihmt.unl.pt

Consulta do Viajante e Medicina Tropical
T +351 213 652 630
T +351 213 652 690
T +351 91 182 37 48
T +351 91 182 44 67
medicina.viagens@ihmt.unl.pt

  • Ensino
  • Investigação
  • Medicina Tropical
  • Cooperação
  • Portal de Denúncias UNL

NOVA University of Lisbon Logo

Siga-nos

  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube

Receber a “newsletter”

© Copyright 2025 IHMT-UNL Todos os Direitos Reservados.
  • Universidade Nova de Lisboa
  • Fundação para a Ciência e a Tecnologia

    UIDB/04413/2020
    UIDP/04413/2020

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok